HTRF Human & Mouse Phospho-Rb (Ser807/811) Detection Kit-Revvity
Order
Cat.No Name Size
64RBS807PEH HTRF RB P-S807/811 KIT 10K PTS
64RBS807PEY HTRF RB P-S807/811 KIT 50K PTS

 

  • Product overview
  • Brand introduction
  • Q&A
  • Data download

This HTRF cell-based assay conveniently and accurately quantifies phosphorylated Retinoblastoma protein at Ser807/811. Rb belongs to the pocket protein family, and acts as a tumor suppressor, regulating cell cycle progression. The active underphosphorylated Rb form interacts and represses the transcriptional activity of E2F factors, thereby preventing G0/G1 cell cycle transition and progression in the cell cycle. In the presence of mitogenic signals, cyclin D-CDK4/6, followed by cyclin E-CDK2, sequentially phosphorylate and inactivate Rb, releasing the E2F transcription factors required for cell cycle progression.

Specifications

 

 

How it works

Phospho-Rb (Ser807/811) assay principle

The Phospho-Rb (Ser807/811) assay measures Rb when phosphorylated at Ser807/811. Unlike Western Blot, the assay is entirely plate-based and does not require gels, electrophoresis, or transfer. The Phospho-Rb (Ser807/811) assay uses 2 labeled antibodies, one with a donor fluorophore, the other with an acceptor. The first antibody is selected for its specific binding to the phosphorylated motif on the protein, the second for its ability to recognize the protein independent of its phosphorylation state. Protein phosphorylation enables an immune-complex formation involving the two labeled antibodies, which brings the donor fluorophore into close proximity to the acceptor, and thereby generates a FRET signal. Its intensity is directly proportional to the concentration of phosphorylated protein present in the sample, and provides a means of assessing the protein's phosphorylation state under a no-wash assay format.

 

phospho-rb-ser807-s811-assay-kit-principle

 

 

Phospho-Rb (Ser807/811) two-plate assay protocol

The two-plate protocol involves culturing cells in a 96-well plate before lysis, then transferring lysates into a low volume detection plate (either HTRF 384-lv or 96-lv plate) before the addition of HTRF Phospho-Rb (Ser807/811) detection reagents. This protocol enables the cells' viability and confluence to be monitored.

 

phospho-rb-ser807-ser811-cellular-assay-2-plate-assay-protocol

 

 

Phospho-Rb (Ser807/811) one-plate assay protocol

Detection of Phosphorylated Rb (Ser807/811) with HTRF reagents can be performed in a single plate used for culturing, stimulation, and lysis. No washing steps are required. This HTS designed protocol enables miniaturization while maintaining robust HTRF quality.

 

phospho-rb-ser807-ser811-1-plate-assay-protocol

 

 

Assay validation

In HCT-116 cells, the CDK4/CDK6 inhibitor, Palbociclib, efficiently inhibits Retinoblastoma phosphorylation on Ser807/811 residue

 

HCT-116 cells were plated at 50 µL in 96-well plates (50,000 cells/well) in complete culture medium and incubated at 37°C, 5% CO2. After 6 hours, cells were treated with increasing concentrations of Palbociclib (50 µL additional volume) for 19 hours.

 

After medium removal, cells were then lysed with 50 µL of supplemented lysis buffer for 30 minutes at RT under gentle shaking, and 16 µL of lysate were transferred into a low volume white microplate before the addition of 4 µL of the premixed HTRF Phospho-Rb (Ser807/811) or Total-Rb detection reagents. The HTRF signal was recorded after 4h of incubation.

 

Treatment with Palbociclib, a Cyclin-Dependent Kinase (Cdk4 and Cdk 6) inhibitor, leads to a significant decrease in the phosphorylation of Rb on Serine 807/811, associated with a decrease in the total amount of the protein (as previously reported by Liu et al, Plos 2017).

 

assay-validation-rb-phospho-s807-801-1

 

 

Phospho-Rb cellular assay validation on human and mouse cell lines

NIH 3T3, C2C12, and HTC116 cells were plated at 100,000 cells per well in 96-well plates. After an ON incubation at 37°C, 5% CO2, cell culture medium was removed and 50µL of lysis buffer was added to the cells. A lysis step was carried out, shaking gently for 30 minutes. 16µL of samples were transferred into a 384-well small volume plate, then 4µL of each of the three HTRF Rb detection reagents were added. Signals were recorded after 4 hours.

 

Both HTRF phospho assays are compatible with mouse models.

 

assay-validation-rb-phospho-s807-801-2

 

 

HTRF assay compared to Western Blot using Phospho-Rb Ser807/811 cellular assay on human HCT116 cells

Human HCT116 cells were cultured in a T175 flask at 5% CO2, 37°C. At 80% of confluency, cells were lysed and soluble supernatants were collected via centrifugation. Serial dilutions of the cell lysate were performed and 16 µL of each dilution were transferred into a 384-well low volume white microplate, before finally adding Phospho-Ser807/811 Rb cellular kit reagents. A side by side comparison showed the HTRF phospho assay is at least 27-fold more sensitive than the Western Blot.

 

assay-validation-rb-phospho-s807-801-3

 

 

Simplified pathway

The Retinoblastoma protein in the cell-division cycle

 

The 110 kDa Retinoblastoma protein Rb belongs to the pocket protein family comprising p107 and p130.

 

Rb acts as a tumor suppressor, regulating cell cycle progression.

 

Mutations inactivating the protein result in the development of retinoblastoma cancer, where retinal cells are not replaced and are subjected to high levels of mutagenic UV radiation.

 

In the absence of mitogenic signals, active underphosphorylated Rb binds and inhibits the E2F transcription factors which are required for the entry into the S phase.

 

By keeping E2F inactivated, Rb maintains the cell in the G1 phase, preventing progression through the cell cycle.

 

In the presence of mitogenic signals, Rb is sequentially phosphorylated and inactivated by cyclin D-CDK4/6 and cyclin E-CDK2. This phosphorylation event induces the release of E2F transcription factors.

 

Finally, E2F activates the transcription of genes such as cyclins, Cdk, Thymidine kinase, or PCNA, which play essential roles in DNA synthesis and replication, as well as in cell division.

 

pathway-rb-phopsho-s807-811-63adk105peg

 

Revvity, we regard "impossibility" as inspiration and "inability" as the driving force. Revvity offers health science solutions, cutting - edge technologies and professional services, with its business covering the entire end - to - end process of scientific research exploration, development, diagnosis, and treatment. Relying on years of in - depth cultivation in fields such as translational multi - omics technology, biomarker identification, imaging, disease prediction, screening, detection and diagnosis, and informatics, Revvity is using the power of technology to break through the boundaries of human potential.

 

In 2023, Revvity's turnover exceeded $2.7 billion. It has more than 11,000 employees worldwide and provides diverse services for customers such as pharmaceutical and biotechnology enterprises, diagnostic laboratories, scientific research institutions and government agencies. The company is a member of the S&P 500 Index, and its customers are spread across more than 190 countries and regions around the world.

×